Because this can be offset by the more efficient conversion to GCV-TP in patients with NUDT15 deficiency, sufficient exposure to active drug metabolite may still be achievable with clinical response to GCV in these subjects. This evidence concerns the gene NUDT15 and hyperinsulinemic hypoglycemia, familial, 4.